NIKI.US Niki BioSolutions, Inc.

Healthcare Biotechnology USA Stocks
1.75 USD
Close of Nov 15, 2026
1.42 17.20
Market cap
USD 5.15M
P/E
-
P/B
0.06x
ROE
-5.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is NIKI.US undervalued?

Graham number

The Graham number of Niki BioSolutions, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Niki BioSolutions, Inc. fundamental analysis

No fundamental analysis for Niki BioSolutions, Inc. yet.

Niki BioSolutions, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Niki BioSolutions, Inc.

Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment…

Full company profile